Linden Josephine 4

What Happened

• Linden Josephine, a director of Innoviva, was granted equity awards upon her appointment to the board on May 18, 2026. The Form 4 reports three grant entries totaling 24,360 units: 5,733 RSUs (grant A), 9,461 RSUs (grant A), and 9,166 derivative units (options) (grant A). Each grant is reported at $0.00 per share/option (total reported value $0).

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (filed within the typical 2-business-day window).
• Reported prices: $0.00 for each grant (standard reporting for awards/options at grant).
• Shares/units granted: 5,733 RSUs + 9,461 RSUs + 9,166 derivative/options = 24,360 total.
• Shares owned after transaction: Not specified in this Form 4.
• Footnotes of note:
  • F1: RSUs and non‑statutory stock options were granted upon board appointment.
  • F2: The RSUs vest in equal installments on each of the first two anniversaries of May 18, 2026.
  • F3: Options and additional RSUs vest at the sooner of the next annual meeting or the one‑year anniversary, subject to continued service; vesting may accelerate for death, disability, or a defined change in control (subject to conditions).

Context

• These are equity grants (awards), not open‑market purchases or sales, and are commonly part of board compensation—such grants do not by themselves indicate a director's trading sentiment.
• The 9,166-unit "derivative" entry reflects option awards rather than immediate stock ownership; vesting and any exercise would occur later per the plan terms above.